Alnylam Pharmaceuticals has entered into a collaboration and license agreement with Roche and Genentech for the joint development of pharmaceutical products containing zilebesiran, with Roche making an upfront payment of $310 million and potential contingent payments of up to $2.5 billion based on milestones achieved.